These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34220581)

  • 1. Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.
    Gilbert JR; Galiano CS; Nugent AC; Zarate CA
    Front Psychiatry; 2021; 12():673159. PubMed ID: 34220581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.
    Lundin NB; Sepe-Forrest L; Gilbert JR; Carver FW; Furey ML; Zarate CA; Nugent AC
    J Affect Disord; 2021 Jan; 279():239-249. PubMed ID: 33074143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans.
    Muthukumaraswamy SD; Shaw AD; Jackson LE; Hall J; Moran R; Saxena N
    J Neurosci; 2015 Aug; 35(33):11694-706. PubMed ID: 26290246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder.
    Nugent AC; Ballard ED; Gilbert JR; Tewarie PK; Brookes MJ; Zarate CA
    Front Psychiatry; 2020; 11():519. PubMed ID: 32655423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine.
    Sumner RL; McMillan RL; Forsyth A; Muthukumaraswamy SD; Shaw AD
    Transl Psychiatry; 2024 Feb; 14(1):116. PubMed ID: 38402231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
    Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
    de la Salle S; Phillips JL; Blier P; Knott V
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
    Bottemanne H; Morlaas O; Claret A; Sharot T; Fossati P; Schmidt L
    JAMA Psychiatry; 2022 Nov; 79(11):1124-1132. PubMed ID: 36169969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression.
    Ballard ED; Greenstein D; Reiss PT; Crainiceanu CM; Cui E; Duncan WC; Hejazi NS; Zarate CA
    Transl Psychiatry; 2024 Jun; 14(1):238. PubMed ID: 38834540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Neuroimage Clin; 2018; 20():92-101. PubMed ID: 30094160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
    Ibrahim L; Diazgranados N; Franco-Chaves J; Brutsche N; Henter ID; Kronstein P; Moaddel R; Wainer I; Luckenbaugh DA; Manji HK; Zarate CA
    Neuropsychopharmacology; 2012 May; 37(6):1526-33. PubMed ID: 22298121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
    J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
    Mathew SJ; Murrough JW; aan het Rot M; Collins KA; Reich DL; Charney DS
    Int J Neuropsychopharmacol; 2010 Feb; 13(1):71-82. PubMed ID: 19288975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.